4 IN THE LUNG RUN
Towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening
2020-2025
4-IN-THE-LUNG-RUN is the first multi-centred implementation trial on volume Computerized tomography (CT) lung cancer screening amongst 24,000 males and females, at high risk for developing lung cancer. The heart of the project is a randomised controlled trial evaluating whether it is safe to have risk-based less intensive screening intervals after a negative baseline CT. This proposal will form the evidence base for risk-based lung cancer screening with huge benefits for the EU, on health outcomes, cost savings, and innovation in the long run.
BOOST Project
Boost access and quality of community-based communicable disease services for PWUD in the EU and neighbouring countries
2023-2024
The main aim of the BOOST project is to enhance the implementation of high-quality community-based communicable disease services as part of a comprehensive, people-centred, and integrated harm reduction approach in five key areas: inform, improve, support, connect and act. These objective is set in a context in which the HIV/AIDS and viral hepatitis epidemics pose a burden to public health in Europe and disproportionately affect people who use drugs (PWUD) and other vulnerable populations that lack access to health services. Addressing these epidemics among PWUD will improve the health of affected communities and public health in Europe in general.
2022-2024
Since cancer is now being targeted through a novel integration of genomics in clinical care and public health, CAN.HEAL is an EU initiative that has the goal of acting as a flagship for cooperation among member states and regional authorities, bridging the gap between public health genomics and diagnostics. The project wishes to set the framework for integrating the Genome of Europe biobanking initiative into public health genomics for cancer.
2021-2024
CANCERLESS’ vision is to prevent cancer and allow for early diagnoses in the homeless population by delivering person-centred interventions to overcome health inequalities and facilitating timely access to quality cancer prevention and screening services for homeless people and leaving no one behind in Europe.
2014-2017
Cancon contributed in different ways to reducing the cancer burden in the EU. It helped raise cancer survival and reduce cancer mortality by improving the quality of cancer care among member states, Improving the quality of life of cancer patients and survivors with proposals on survivorship and ensuring reintegration and palliative care and a decrease in inequalities at various levels of the cancer control field.
2022-2024
CanScreen aims to collect information on the characteristics and performance of cancer screening programmes across the globe in a harmonized manner and to disseminate the information for improved programme management and informed policy-making. The core objective of CanScreen5 is to encourage and support countries to collect and use cancer screening data for effective programme evaluation and quality improvement.
2024-2028
EU-JAMRAI 2 seeks to implement concrete actions to monitor, prevent and effectively tackle antimicrobial resistance across human, animal and environmental health domains, empowering participating countries to strengthen their national action plans. The mission is to reduce the risk of European citizens’ exposure to antimicrobial-resistant bacteria. This involves promoting integrated surveillance and strengthening infection prevention through the “One Health” approach, while improving the care of patients with bacterial infections, guaranteeing access to effective and proportionate antibiotic therapy, for instance.
2020-2023
The overall aim of CAPABLE is to combine the most advanced technologies for data and knowledge management with a sound socio-psychological approach in order to develop a coaching system for improving the quality of life of cancer home patients. The system aims at early detecting and managing cancer-related issues and at satisfying the needs of patients and their home caregivers.
2023-2026
Comprehensive Cancer Centres and Comprehensive Cancer Care Networks may be the core of Comprehensive Cancer Infrastructures (CCIs) that deliver quality care and provide resources to improve and integrate care, research, and education. Data already available confirm that the level of “CCI maturity” in Member States is widely different from some countries lacking CCIs completely. A European initiative, implemented in all Member States, based on a capacity building programme (CBP), will help reduce inequalities, in the context of other actions ongoing, such as CRANE, JANE and UNCAN.
2022-2027
CGI-Clinics aims at improving personalized medicine in oncology by optimizing genomic data interpretation (after sequencing and before advising on compatible targeted therapies). The interpretation of tumor genomic data relies on the work of experts reviewing scattered databases and resources, in a time-consuming process that may lead to suboptimal clinical decisions. CGI-clinics will systematize the interpretation process by integrating relevant public and private databases hospitals in a one-stop shop tool, with the possibility to organize virtual molecular tumor boards co-facilitated by reference hospitals.
2023-2025
CORE aims to reduce inequalities in the HIV, TB and viral hepatitis responses by promoting, strengthening and integrating the community responses that have proven key in reaching communities traditionally underserved by mainstream prevention and healthcare services.
2022-2024
The CraNE Joint Action is proposed for funding in response to the flagship number 5 of the Europe’s Beating Cancer Plan, which defines that the European Commission will establish by 2025, an EU Network linking recognised National Comprehensive Cancer Centres (CCCs) in every Member State. The aim of CraNE is to build upon of the outcomes of previous CanCon and iPAAC Joint Actions, preparing the necessary preconditions, either administrative or professional and especially those related to high-quality performance and access for the patient.
2023-2026
Up-skilling and re-skilling the health care workforce in the cancer care setting, which then, in return, support the development of effective, person-centred health care, digital cancer care services and the use of contemporary eHealth technology by the HCPs
2023-2027
Discovering the Causes of Three Poorly Understood Cancers in Europe (DISCERN) is a five-year project of the European Commission Cancer Mission to understand the causes of renal, pancreatic, and colorectal cancer in Europe and to help explain the geographical distribution of these cancer types, including their high incidence in central and eastern Europe.
2023-2026
ECHoS is a new European consortium supported by the EU Mission on Cancer which will support member states and associated countries to gradually create National Cancer Mission Hubs (NCMHs). These NCMHs will be essential in involving all relevant stakeholders to engage them in collaborative initiatives and policy dialogues on cancer at national and regional levels.
2018-2021
eHAction is the Joint Action supporting the eHealth Network, which, in its Multiannual Work Programme 2018-2021, sets targets for exploring eHealth to facilitate the management of chronic diseases and multi-morbidity, by increasing sustainability and efficiency of health systems, and by facilitating personalized care and empowering the citizen.
2024-2026
The ELISAH project aims to reduce the burden of breast cancer by acting on modifiable risk factors and involving NGOs and patient groups. It will develop different strategies that integrate structural interventions and individual health promotion, and the relationships between risk factors. The project is articulated around studying environmental pollution, the built environment, exposure to unhealthy nutrition, lack of physical activity, as well as alcohol and tobacco use.
2021-2025
The main objective of EUREST-RISE is to support an integrative series of research studies to facilitate the training of researchers (ESR and ER) to examine tobacco product systems, their mechanisms and purpose, and interactions between key design characteristics and their assessment in populations of users.
2019-2024
HEADSpAcE is a unique study that will investigate multiple reasons for the poor prognosis of head and neck cancers, including individual and structural reasons for late diagnosis; the influence of lifestyle, infectious, and genetic factors on poor outcome; and the adherence to clinical guidelines in various settings. The project aims to identify the most appropriate method of diagnosing cancer caused by human papillomavirus (HPV), and to provide genomic evidence of strong predictors of prognosis that will have the potential to improve care and reduce treatment-related morbidity. Guidelines will be developed for implementation in clinical care.
2022-2026
The IMMUNO-model COST Action aims to foster research and innovation in the field of preclinical immune-oncology models with the ultimate goal of advancing in the treatment of cancer patients by improving their outcomes and quality of life. IMMUNO-model will bring together European researchers from diverse sectors (academia, clinical, industry) with the common goal of establishing a Network that endorses immuno-oncology research by specifically promoting the sharing, standardization and application of immunotherapy preclinical models. This Action will allow the implementation of a broad, creative and collaborative hub through the organization of community-building activities, the creation of synergies among European and non-European scientists, and the training of future researchers in the field.
2023-2026
INTERACT-EUROPE brings together 33 partners from 17 countries aiming to develop a European inter-specialty cancer training programme involving all main oncology disciplines and professions, cancer centres and patient groups, based on relevant needs assessments. The project will foster a patient-centric approach to quality cancer care through the promotion of multi-disciplinary and multi-professional teamwork.
2018-2021
The Innovative Partnership for Action Against Cancer (iPAAC) Joint Action brings together 24 Associated Partners (with Affiliated Entities, 44 partners) across Europe whose main objectives are to build upon deliverables of the CANCON Joint Action and to implement innovative approaches to cancer control.
2022-2024
JANE is a Joint Action aiming at establishing seven new Networks of Expertise in the cancer field in the following domains: personalized primary prevention; survivorship; palliative care; omic technologies; hi-tech medical resources; one or more complex & poor-prognosis cancer(s); young adults with cancer. The Joint Action has two goals: to prepare everything necessary to launch the new Networks of Expertise and to critically evaluate existing models of current and future EU networking with a view to optimizing the functioning of the new Networks of Expertise.
2024-2028
Cancer and other non-communicable diseases (NCDs) represent a significant portion of the disease burden in Europe, much of which is preventable. The Joint Action Prevent Non-Communicable Diseases (JA PreventNCD) project is designed to address this challenge by supporting strategies and policies that aim to reduce the burden of cancer and NCDs, focusing on both personal and societal risk factors.
2021-2024
The general objective of JATC2 is not only to support the implementation of the Tobacco Products Directive (TPD) and Tobacco Advertising Directive (TAD), but also to promote activities consistent with the objectives of the WHO Framework Convention on Tobacco Control (FCTC). The JATC1 contributed to the implementation of the TPD in specific areas of laboratory capacity, testing methods for tobacco and related products, regulation of ingredients and developed data sharing agreements concerning the excessive amounts of data within EU-CEG.
2022-2024
In childhood, adolescence and young adults (CAYA), melanoma is under-studied and non-existing tailored clinical guidelines and standardized approaches lead to a very low diagnostic accuracy. Against this background, the MELCAYA project aims to understand risk factors and determinants of melanoma to improve the prevention, diagnosis and prognosis of melanomas in CAYA.
2020-2026
OncNGS consortium wishes to develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients, forever. challenge will consist in providing efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of pan-cancer tumour marker analysis kit including NGS analysis integrated with an ICT decision support system including analytical test interpretation and reporting.
ONCODIR
Evidence-based Participatory Decision Making for Cancer Prevention through implementation research
2023-2026
Colorectal cancer (CRC) is one of the most common cancer types and its increased occurrence may be attributable to adverse health behaviours, especially in lower socioeconomic status populations. Stemming from the specific risk factors identified with CRC, ONCODIR integrates multidisciplinary research methods from health policy analytics; social and behavioural science; AI-powered multi-omics and retrospective data analytics as well as decision support theories to deliver evidence-based cancer prevention programmes and innovative AI-powered personalised prevention approaches
2020-2023
ONCORELIEF is a digital platform that can be used to overcome challenges related to the quality of life after cancer treatment. It offers a user-friendly application, called Guardian Angel (GA), which collects user data in order to offer support for post-treatment activities and tasks, suggest actions regarding the person’s overall health status, improved quality of life and active health care and keep them engaged on a wellness journey that will protect their health over the prolonged post-cancer treatment period.
PanCareFollowUp (PFCU)
Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers
2019-2023
PanCareFollowUp is an EU-funded project looking at how to best deliver survivorship care to survivors of childhood and adolescent cancer in Europe.
PanCareSurPass (PCSP)
PanCare studies of the scale-up and implementation of the digital Survivorship Passport to improve people-centred care for childhood cancer survivors
2021-2025
The overall aim of PCSP is to leverage the digital transformation of healthcare to improve person-centred care for survivors of childhood and adolescent cancer by scaling up and implementing an interoperable Survivorship Passport (SurPass) v2.0 across Europe.
2023-2027
The main purpose of the PIECES project is to adapt and implement existing evidence-based programmes to improve implementation out outcomes and by that, improve reach and effectiveness of primary prevention programmes in real-world settings. PIECES will address a wide range of risk factors and focus on the specific behaviour change mechanisms that promote healthy behaviours associated with a reduction of cancer incidence among the European Union (EU) population and beyond. The main modifiable risk factors that the project is aiming to tackle include: 1) Tobacco smoking and exposure to second-hand smoke, 2) Alcohol consumption, 3) Poor physical activity, 4) HPV Infection, 5) Sun exposure, and 6) Diet. We will not test PCP programmes for their effectiveness; the focus is on implementation processes and outcomes.
2023-2026
PRAISE-U encourages early detection and diagnosis of prostate cancer through customised and risk-based screening programmes. The goal is to align protocols and guidelines across Member States and enable the collection and distribution of relevant data to reduce prostate cancer morbidity and mortality rates in Europe.
2021-2024
The Prevention and Screening Innovation Project Towards Elimination of Cervical Cancer (PRESCRIP-TEC) is a three-year project (February 2021 – January 2024) that focuses its research on increasing the adoption of cervical cancer screening in resource-poor or hard-to-reach settings of Bangladesh, India, Uganda and Slovakia.
PRESCRIP-TEC leads to effective and innovative cervical cancer screening, including direct treatment and follow-up for women in these four countries, improving availability, accessibility, acceptability and, quality of health care services.
2023-2025
The ambition of the PREVENTABLE project is to merge specialized clinical knowledge on Rare Tumour Risk Syndromes (RTRS) pathways of care, real life clinical data from RTRS patients and experiences from professionals and patients, with health economic models and social sciences approaches to estimate the cost-benefit of risk-reduction interventions in RTRS and delineate guidelines for its communication among and within clinical teams and RTRS patients. PREVENTABLE project results will be delivered to a diversity of stakeholders, including policymakers, in order to promote the implementation of cost-effective RTRS patient-centred care in Europe.
2023-2024
PROTECT-EUROPE is an EU4Health Project that champions gender-neutral vaccination programme in EU Member States to provide protection for everyone against cancers caused by HPV e.g. cervical, anal, penile, vaginal, vulval and oropharyngeal. Gender-neutral HPV vaccination is one of the flagship commitments of Europe’s Beating Cancer Plan.
2022-2025
RaDAR project aims to address the European urgent need of a rapid detection and effective infection control system for antimicrobial resistance (AMR) through the implementation of a value-based cross-border collaborative procurement of innovative solutions. The common identification of the needs by a cross-border group of 4 procurement organisations (from ES, FR and IT) will promote an increased impact of the adopted innovation and will collaboratively give response to the current AMR problem affecting the European Union (EU).
2020-2024
RISCC is a multidisciplinary consortium of key researchers in the field of HPV, HPV screening and HPV vaccination, which aims to develop and evaluate the first risk-based screening program for cervical cancer, provide open-source implementation tools and contribute to the elimination of cervical cancer in Europe.
2023-2026
Solace is an EU projects that aims to assess the current state of policies, needs, and best practices of Lung Cancer Screening (LCS) in EU member states and produce a comprehensive guideline and implementation package covering all steps of the lung cancer screening pathway.
2023-2026
TANGERINE is an artificial-intelligence (AI)-based study aimed at predicting cancer immunotherapy response in patients with different types of cancer. The project primary goal is to develop, validate and openly publish an AI system which can predict ICIs response based on routine histopathology slides, Computed Tomography (CT) scan images and routine clinical data. As co-primary aims, disease-free survival, overall survival and toxicity will be predicted. The secondary goal is to validate the capacity of this system to identify cellular structures and image patterns associated with ICI response and toxicity that explain model predictions (explainability). This aim is exploratory and qualitative
2021-2023
TEHDAS, the joint action Towards the European Health Data Space, helps EU member states and the European Commission to develop and promote concepts for the secondary use of health data to benefit public health and health research and innovation in Europe. Their goal is that in the future European citizens, communities and companies will benefit from secure and seamless access to health data regardless of where it is stored.
2023-2026
The TOGAS project aims at contributing to the improvement and fostering of health in the European Union by decreasing the burden, caused by gastric cancer. More precisely, TOGAS contributes to the Flagship 4 of the Europe’s Beating Cancer Plan: putting forward a new EU-Supported Cancer Screening Scheme, particularly, by developing novel approaches for screening and early detection of gastric cancer, and by providing options to extend screening for new cancers that are currently not included in the Recommendations of the European Council.
2023 – 2025
The TRANSiTION project aims to create a new state-of-the-art education and training programme for informal carers, clinical and non-clinical professionals that will empower them to acquire the digital skills and competencies required to meet the current and future needs of effective cancer care. This training programme will up- and re-skill the workforce while also supporting a swifter transition to more cost-effective and patient-centred health models.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.
OUR X
@ecan_ja @sciensano @iMedPhysAUTH @NIO_PIB I am pleased that the results of our work package will be presented to the public [digital + cancer] health crowd tomorrow.
See you there!!
@goeg_at @euphadhai @PHMRsection @EU_Health @ecan_ja @ECHoS_CMH
💬 "According to #cancer patients and policy experts, #telemedicine is seen as a useful complementary tool, but not as a replacement for in-person services."
@SchmittTugce, presenting the results of the @ecan_ja foresight study at @EPHconference. #EPH2024 https://ecanja.eu/
📢 Join us at the #EPH2024!
🗓️ Date: Thursday, November 14th
⏰ Time: 11:45 – 12:45
📍 Location: Lisbon, Portugal
➕ info: https://ecanja.eu/event/17th-european-public-health-conference/
#publichealth #EU4Health #HealthUnion